Advertisement

Effects of dopaminergic and serotonergic compounds in rats trained to discriminate a high and a low training dose of the synthetic cathinone mephedrone

  • Iman Saber
  • Andrew Milewski
  • Allen B. Reitz
  • Scott M. Rawls
  • Ellen A. WalkerEmail author
Original Investigation
  • 61 Downloads

Abstract

Rationale

The underlying pharmacological mechanisms of mephedrone, especially as related to interactions with different neurotransmitter systems, are a critical area of study as mephedrone continues to be abused.

Objective

Direct-acting 5-HT2A/2C receptor agonists and antagonists and D1–3 receptor antagonists were examined in two groups of rats trained to discriminate mephedrone. A high dose of mephedrone was trained to extend previous results with traditional monoamine transporter inhibitors and substrate releasers. A very low dose of mephedrone was trained to preferentially capture serotonergic activity and to minimize the influence of rate-decreasing effects on substitution patterns. Selective 5-HT2A/2C and D1–3 receptor antagonists were examined in both groups.

Methods

Male Sprague-Dawley rats were trained to discriminate either a low dose of 0.5 mg/kg mephedrone (N = 24) or a high dose of 3.2 mg/kg mephedrone (N = 11) from saline.

Results

In the low training-dose group, mephedrone, MDMA, methamphetamine, d-amphetamine, cocaine, and enantiomers of mephedrone substituted for mephedrone; mCPP partially substituted overall for mephedrone; and DOI, WAY163909, and morphine failed to substitute for mephedrone. In the high training-dose group, only mephedrone and MDMA substituted for mephedrone. Sulpiride produced a small antagonism of the low training dose of mephedrone while SCH23390, SB242084, and ketanserin altered response rates.

Conclusions

A lower training dose of mephedrone produces a discriminative stimulus fully mimicked by MDMA, methamphetamine, cocaine, and d-amphetamine, whereas a higher training dose of mephedrone requires a discriminative stimulus that was only mimicked by MDMA. Dopaminergic or serotoninergic antagonists failed to produce significant blockade of mephedrone at either training dose.

Keywords

Drug discrimination Ketanserin MDMA Mephedrone Methamphetamine Psychostimulants Rats SB242084 SCH23390 Sulpiride 

Notes

Acknowledgments

The authors wish to thank Drs. Ellen Unterwald and Sara Jane Ward for their intellectual contributions and initial readings of this manuscript. Funding sources: R21DA032718, R01DA039139 and P30 DA013429-16.

References

  1. Aarde SM, Angrish D, Barlow DJ, Wright MJ Jr, Vandewater SA, Creehan KM et al (2013) Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Sprague-Dawley and Wistar rats. Addict Biol. 2013 18:786–799Google Scholar
  2. Baumann MH, Ayestas MA Jr, Partilla JS, Sink JR, Shulgin AT, Daley PF, Brandt SD, Rothman RB, Ruoho AE, Cozzi NV (2012) The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue. Neuropsychopharmacology. 37:1192–1203CrossRefGoogle Scholar
  3. Baumann MH, Walters HM, Niello M, Sitte HH (2018) Neuropharmacology of synthetic cathinones. Handb Exp Pharmacol Nov 8.  https://doi.org/10.1007/164_2018_178
  4. Berquist MD, Fantegrossi WE (2018) Discriminative stimulus effects of psychostimulants. Curr Top Behav Neurosci 39:29–49CrossRefGoogle Scholar
  5. Berquist MD II, Thompson NA, Baker LE (2017) Evaluation of training dose in male Sprague-Dawley rats trained to discriminate 4-methylmethcathinone. Psychopharmacology 234(21):3271–3278CrossRefGoogle Scholar
  6. Bonano JS, Banks ML, Kolanos R, Sakloth F, Barnier ML, Glennon RA, Cozzi NV, Partilla JS, Baumann MH, Negus SS (2015) Quantitative structure-activity relationship analysis of the pharmacology of para-substituted methcathinone analogues. Br J Pharmacol 172(10):2433–2444.  https://doi.org/10.1111/bph.13030 CrossRefGoogle Scholar
  7. Callahan PM, Cunningham KA (1994) Involvement of 5-HT2C receptors in mediating the discriminative stimulus properties of m-chlorophenylpiperazine (mCPP). Eur J Pharmacol 257(1–2):27–38CrossRefGoogle Scholar
  8. Callahan PM, Appel JB, Cunningham KA (1991) Dopamine D1 and D2 mediation of the discriminative stimulus properties of d-amphetamine and cocaine. Psychopharmacology 103(1):50–55CrossRefGoogle Scholar
  9. Creehan KM, Vandewater SA, Taffe MA (2015) Intravenous self-administration of mephedrone, methylone and MDMA in female rats. Neuropharmacology 92:90–97CrossRefGoogle Scholar
  10. DeLarge AF, Erwin LL, Winsauer PJ (2017) Atypical binding at dopamine and serotonin transporters contribute to the discriminative stimulus effects of mephedrone. Neuropharmacology 119:62–75CrossRefGoogle Scholar
  11. Eshleman AJ, Wolfrum KM, Hatfield MG, Johnson RA, Murphy KV, Janowsky A (2013) Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 85(12):1803–1815CrossRefGoogle Scholar
  12. Gannon BM, Fantegrossi WE (2016) Cocaine-like discriminative stimulus effects of mephedrone and naphyrone in mice. J Drug Alcohol Res 5:art236009.  https://doi.org/10.4303/jdar/236009 CrossRefGoogle Scholar
  13. Gatch MB, Taylor CM, Forster MJ (2013) Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 24:437–447CrossRefGoogle Scholar
  14. Gommans J, Hijzen TH, Maes RA, Olivier B (1998) Discriminative stimulus properties of mCPP: evidence for a 5-HT2C receptor mode of action. Psychopharmacology 137(3):292–302CrossRefGoogle Scholar
  15. Goodwin AK, Baker LE (2000) A three-choice discrimination procedure dissociates the discriminative stimulus effects of d-amphetamine and (+/−)-MDMA in rats. Exp Clin Psychopharmacol 8(3):415–423CrossRefGoogle Scholar
  16. Goodwin AK, Pynnonen DM, Baker LE (2003) Serotonergic-dopaminergic mediation of MDMA's discriminative stimulus effects in a three-choice discrimination. Pharmacol Biochem Behav 74:987–995CrossRefGoogle Scholar
  17. Gregg RA, Baumann MH, Partilla JS, Bonano JS, Vouga A, Tallarida CS, Velvadapu V, Smith GR, Peet MM, Reitz AB, Negus SS, Rawls SM (2015) Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats. Brit J Pharmacol 72(3):883–894CrossRefGoogle Scholar
  18. Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC et al (2011) 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 339:530–536CrossRefGoogle Scholar
  19. Harvey EL, Baker LE (2016) Differential effects of 3,4-methylenedioxypyrovalerone (MDPV) and 4-methylmethcathinone (mephedrone) in rats trained to discriminate MDMA or a d-amphetamine + MDMA mixture. Psychopharmacology 233:673–680CrossRefGoogle Scholar
  20. Harvey EL, Burroughs RL, Baker LE (2017) Effects of D1 and D2 receptor antagonists on the discriminative stimulus effects of methylendioxypyrovalerone and mephedrone in male Sprague-Dawley rats trained to discriminate D-amphetamine. Behav Pharmacol 28:586–589CrossRefGoogle Scholar
  21. Kehr J, Ichinose F, Yoshitake S, Goiny M, Sievertsson T, Nyberg F, Yoshitake T (2011) Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 164:1949–1958CrossRefGoogle Scholar
  22. Kuczenski R, Segal DS, Cho AK, Melga W (1995) Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to stereoisomers of amphetamine and methamphetamine. J Neurosci 15:1308–1317CrossRefGoogle Scholar
  23. Lisek R, Xu W, Yuvasheva E, Chiu YT, Reitz AB, Liu-Chen LY, Rawls SM (2012) Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend 126:257–262CrossRefGoogle Scholar
  24. Luethi D, Kolaczynska KE, Docci L, Krahenbuho S, Hoener MC, Liechti ME (2018) Pharmacological profile of mephedrone analogs and related new psychoactive substances. Neuropharmacology 134:4–12CrossRefGoogle Scholar
  25. Martinez-Clemente J, Escubedo E, Pubill D, Camarasa J (2012) Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsychopharmacol 22:231–236CrossRefGoogle Scholar
  26. Matsumoto T, Maeno Y, Kato H, Seko-Nakamura Y, Monma-Ohtaki J, Ishiba A (2014) 5-hydroxytryptamine- and dopamine-releasing effects of ring-substituted amphetamines on rat brain: a comparative study using in vivo microdialysis. Eur Neuropsychopharmacol 24:1362–1370CrossRefGoogle Scholar
  27. Pettibone DJ, Williams M (1984) Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 33(9):1531–1535CrossRefGoogle Scholar
  28. Philogene-Khalid HL, Simmons SJ, Nayak S, Martorana RM, Su SH, Caro Y, Ranieri B, DiFurio K, Mo L, Gentile TA, Murad A, Reitz AB, Muschamp JW, Rawls SM (2017a) Stereoselective differences between the reinforcing and motivational effects of cathinone-derived 4-methylmethcathinone (Mephedrone) in self-administering rats. ACS Chem Neurosci 8(12):2648–2654.  https://doi.org/10.1021/acschemneuro.7b00212 CrossRefGoogle Scholar
  29. Philogene-Khalid HL, Smith GR, Reitz AB, Liu-Chen L, Rawls SM (2017b) S enantiomer of the synthetic cathinone mephedrone reduces anxiety- and depressant-like effects caused by cocaine or MDPV withdrawal in rats. Drug Alcohol Depend 178:119–125.  https://doi.org/10.1016/j.drugalcdep.2017.04.024 CrossRefGoogle Scholar
  30. Pigott A, Frescas S, McCorvy JD, Huang XP, Roth BL, Nichols DE (2012) Trans-2-(2,5-Dimethoxy-4-iodophenyl)cyclopropylamine and trans-2-(2,5-dimethoxy-4-bromophenyl)cyclopropylamine as potent agonists for the 5-HT(2) receptor family. Beilstein J Org Chem 8:1705–1709.  https://doi.org/10.3762/bjoc.8.194 CrossRefGoogle Scholar
  31. Rickli A, Hoener MC, Liechti ME (2015a) Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. Eur Neuropsychopharmacol 25:365–376CrossRefGoogle Scholar
  32. Rickli A, Luethi D, Reinisch J, Buchy D, Hoener MC, Liechti ME (2015b) Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology 99:546–553CrossRefGoogle Scholar
  33. Roth BL, Driscol J (2018) PDSP Ki database. Psychoactive drug screening program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 26 November 2018Google Scholar
  34. Schenk S, Highgate Q (2018) Dopamine and serotonin antagonists fail to alter the discriminative stimulus properties of ±methylenedioxymethamphetamine. Behav Pharmacol.  https://doi.org/10.1097/FBP.0000000000000442
  35. Simmler LD, Buser TA, Donzelli M, Schramm Y, Dieu L-H, Huwyler J, Chaboz S, Hoener MC, Liechti ME (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470CrossRefGoogle Scholar
  36. Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88:237–244CrossRefGoogle Scholar
  37. Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML (2016) Cocaine-like discriminative stimulus effects of alpha- pyrrolidinovalerophenone, methcathinone and their 3,4-methylenedioxy or 4-methyl analogs in rhesus monkeys. Addict Biol 22:1169–1178.  https://doi.org/10.1111/adb.12399 CrossRefGoogle Scholar
  38. Suyama JA, Sakloth F, Kolanos R, Glennon RA, Lazenka MF, Negus SS, Banks ML (2016) Abuse-related neurochemical effects of para-substituted methcathinone analogs in rats: microdialysis studies of nucleus accumbens dopamine and serotonin. J Pharmacol Exp Ther 36:182–190Google Scholar
  39. Varner KJ, Daigle K, Weed PF, Lewis PB, Mahne SE, Sankaranarayanan A, Winsauer PJ (2013) Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology 225:675–685CrossRefGoogle Scholar
  40. Zea-Ponce Y, Kegeles LS, Guo N, Raskin L, Bakthavachalam V, Laruelle M (2002) Pharmacokinetics and brain distribution in non-human primate of R(−)[123I]DOI, A 5-HT(2A/2C) serotonin agonist. Nucl Med Biol 29:575e583CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmaceutical Sciences, School of PharmacyTemple UniversityPhiladelphiaUSA
  2. 2.Fox Chase Chemical Diversity Center, Inc.DoylestownUSA
  3. 3.Center for Substance Abuse ResearchLewis Katz School of Medicine, Temple UniversityPhiladelphiaUSA
  4. 4.Department of Pharmacology, Lewis Katz School of MedicineTemple UniversityPhiladelphiaUSA

Personalised recommendations